Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 23 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

30%

7 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 3

6(31.6%)

Phase 2

6(31.6%)

N/A

4(21.1%)

Phase 1

2(10.5%)

Phase 4

1(5.3%)

19Total

Phase 3(6)

Phase 2(6)

N/A(4)

Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT06705530Phase 1Completed

A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders

Role: lead

NCT07209059Phase 2Recruiting

PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

Role: lead

NCT06721598Not Yet Recruiting

An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders

Role: lead

NCT06418776Phase 3Recruiting

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

Role: lead

NCT06237192Not ApplicableRecruiting

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Role: lead

NCT06188676Phase 3Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Role: lead

NCT04422470Completed

Registry of Patients With Hematologic Disease and COVID-19 in Russia

Role: lead

NCT05660993Phase 2Unknown

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Role: lead

NCT04898140Completed

The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents

Role: collaborator

NCT05425654Phase 2Recruiting

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Role: lead

NCT05339204Not ApplicableUnknown

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

Role: lead

NCT05158608Phase 3Unknown

Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis

Role: lead

NCT05165719Completed

Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination

Role: lead

NCT04578847Phase 2Unknown

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Role: lead

NCT03462095Not ApplicableUnknown

De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)

Role: lead

NCT01193933Not ApplicableUnknown

Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment

Role: lead

NCT03389919Phase 3Unknown

Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT

Role: lead

NCT02842931Phase 3Unknown

R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

Role: lead

NCT02423837Phase 3Unknown

Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma

Role: lead

NCT02270307Phase 2Unknown

MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis

Role: lead